RxDoctor Payments Data

Jaime Dixon

Family · Huntington, WVNPI 1790068534

Payments from drug & device makers

$5,903in general payments, 2019–2025

Across 440 payments — averaging $13.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • AstraZeneca$640
  • E.r. Squibb & Sons, L.L.C.$523
  • Johnson & Johnson$439
  • Novartis$364
  • Pfizer$235
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,903100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,903 in reported general payments places this provider in the 90th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$43,015
Medicare patients
467
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban67$73,089
EliquisApixaban60$66,438
EntrestoSacubitril/Valsartan32$32,341
BrilintaTicagrelor21$9,217
JardianceEmpagliflozin14$8,872
Metoprolol Succinate464$5,544
Flecainide Acetate82$3,774
Ranolazine ErRanolazine20$1,733
Rosuvastatin Calcium150$1,442
Isosorbide Mononitrate ErIsosorbide Mononitrate96$962
ClopidogrelClopidogrel Bisulfate52$587
Carvedilol80$551
Losartan Potassium70$479
Furosemide105$438
Atorvastatin Calcium41$387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$439$73,08967 claims
PfizerEliquis$235$66,43860 claims
NovartisEntresto$364$32,34132 claims
AstraZenecaBrilinta$640$9,21721 claims
Boehringer IngelheimJardiance$96$8,87214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →